---
title: "Nektar Therap | 8-K: FY2025 Revenue Beats Estimate at USD 55.23 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278942142.md"
datetime: "2026-03-12T20:49:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278942142.md)
  - [en](https://longbridge.com/en/news/278942142.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278942142.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/278942142.md) | [繁體中文](https://longbridge.com/zh-HK/news/278942142.md)


# Nektar Therap | 8-K: FY2025 Revenue Beats Estimate at USD 55.23 M

Revenue: As of FY2025, the actual value is USD 55.23 M, beating the estimate of USD 43.78 M.

EPS: As of FY2025, the actual value is USD -9.73, beating the estimate of USD -9.9265.

EBIT: As of FY2025, the actual value is USD -124.36 M.

The provided reference is a Form 8-K filing by Nektar Therapeutics (内克塔治疗) stating that the company issued a press release on March 12, 2026, announcing its financial results for the quarter ended December 31, 2025. The actual financial results, operational metrics, and any outlook or guidance are contained within the referenced press release (Exhibit 99.1), which is not provided in this document. Therefore, no specific financial or operational metrics, nor any outlook or guidance, can be extracted from the given text.

### Related Stocks

- [Nektar Therapeutics (NKTR.US)](https://longbridge.com/en/quote/NKTR.US.md)

## Related News & Research

- [Nekkar ASA Completes Share Buy-Backs Worth NOK 44.65 Million](https://longbridge.com/en/news/273663404.md)
- [Nanalysis Sets Date for Q4 and Full-Year 2025 Results Call](https://longbridge.com/en/news/281538578.md)
- [Itaú Unibanco Files Q4 2025 Pillar 3 Risk and Capital Report With Strong Capital Ratios](https://longbridge.com/en/news/281508938.md)
- [Scinai Immunotherapeutics reports FY results](https://longbridge.com/en/news/281477360.md)
- [Hooker Furnishings to Host Fourth Quarter and Full Year Earnings Call April 16th | HOFT Stock News](https://longbridge.com/en/news/281625867.md)